medigraphic.com
ISSN 1561-2988 (Impreso)

2015, Número 2

Siguiente >>

Rev Cubana Farm 2015; 49 (2)


Riesgo cardiovascular con el uso de azitromicina

Galán ML, Souto CRD, Valdés GS

Idioma: Español
Referencias bibliográficas: 12
Paginas: 193-196
Archivo PDF: 63.10 Kb.


FRAGMENTO

La azitromicina es un antibiótico macrólido semisintético de amplio espectro y de uso bien frecuente en la población mundial, indicado para el tratamiento de diferentes enfermedades infecciosas.
Existen varios reportes del riesgo cardiovascular asociado al uso de azitromicina y aún no existen estudios convincentes del mecanismo molecular de este efecto.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hancox JC, Hasnain M, Vieweg WV, Breden Crouse EL and Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1(5):155-65.

  2. Maisch NM, Kochupurackal JG, Sin J. Azithromycin and the risk of cardiovascular complications. J. Pharm. Pract. Oct. 2014;27(5):496-500.

  3. Food and Drug Administration. FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. [Citado: 8 de abril de 2013]. Disponible en:http://www.fda.gov/Drugs/DrugSafety/ucm304372.htm

  4. Ray W, Murray K, Hall K, Arbogast P and Stein C. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-90.

  5. Food and Drug Administration (2013) FDA Drug Safety Communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. [citado: 16 abril 2013]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm

  6. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003;116(1185):U666.

  7. Huang BH, Wu CH, Hsia CP, Yin Chen. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30(12):1579-82.

  8. Alfonso I, Calvo DC, Jiménez G, Lara C, Broche L. Azitromicina y efectos cardiovasculares notificados al Sistema Cubano de Farmacovigilancia, 2003-2012. Rev Cubana Farm. 2014;48(3). Disponible en: http://bvs.sld.cu/revistas/far/vol48_3_14/far17314.htm

  9. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704-12.

  10. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311(21):2199-2208.

  11. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99(12):1540-7.

  12. O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290(11):1459-66.




2020     |     www.medigraphic.com